RxDoctor Payments Data

Jun-Ki Park, MD

Nephrology · Stockbridge, GANPI 1861713471

Payments from drug & device makers

$3,309in general payments, 2019–2025

Across 151 payments — averaging $21.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Fresenius USA Marketing, Inc.$692
  • Amgen$349
  • Mallinckrodt Hospital Products Inc.$337
  • Akebia Therapeutics Inc$333
  • Bayer$201
  • Otsuka America Pharmaceutical, Inc.$176
  • plus $1K from 16 others

What the payments were for

  • Food & beverage$2,87987%
  • Education$43013%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,309 in reported general payments places this provider in the 60th percentile of 388 nephrology providers in Georgia.

See all nephrology providers in Georgia

Medicare billing

Part B allowed, 2024
$179,746
Medicare patients
327
Services billed
1,291

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
KerendiaFinerenone170$238,021
VelphoroSucroferric Oxyhydroxide72$217,178
JardianceEmpagliflozin150$195,330
FarxigaDapagliflozin Propanediol175$173,167
AuryxiaFerric Citrate41$125,074
TrulicityDulaglutide34$68,929
MounjaroTirzepatide20$32,442
OzempicSemaglutide14$22,671
Sevelamer Carbonate61$21,977
EntrestoSacubitril/Valsartan13$17,094
VeltassaPatiromer Calcium Sorbitex13$12,865
Cinacalcet Hcl25$5,799
Nifedipine ErNifedipine61$2,130
Eplerenone18$1,795
Hydralazine Hcl79$1,398

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
BayerKerendia$201$238,021170 claims
Fresenius USA Marketing, Inc.Velphoro$692$217,17872 claims
Boehringer IngelheimJardiance$50$195,330150 claims
AstraZenecaFarxiga$155$173,167175 claims
Akebia Therapeutics IncAuryxia$333$125,07441 claims
Lilly USA, LLCTrulicity, Mounjaro$48$101,37154 claims
Novo NordiskOzempic$106$22,67114 claims
NovartisEntresto$154$17,09413 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 388 nephrology providers in Georgia.

Other nephrology in Stockbridge

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →